Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

SABCS 2012

Neurocognitive impact in adjuvant chemotherapy for breast cancer

Prof Bernadine Cimprich - University of Michigan School of Nursing, Ann Arbor, USA

Neurocognitive impact in adjuvant chemotherapy for breast cancer ( Prof Bernadine Cimprich - University of Michigan School of Nursing, Ann Arbor, USA )

Predicting late distant metastases in ER / HER2- breast cancer patients

Dr Peter Dubsky - Medical University of Vienna, Austria

Predicting late distant metastases in ER / HER2- breast cancer patients ( Dr Peter Dubsky - Medical University of Vienna, Austria )

Investigation of Ki67 biomarker

Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada

Investigation of Ki67 biomarker ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )

Results of a randomised phase 2 study of PD 0332991

Dr Richard Finn - Universtity of California, Los Angeles, USA

Results of a randomised phase 2 study of PD 0332991 ( Dr Richard Finn - Universtity of California, Los Angeles, USA )

Eribulin fails to demonstrate superiority over capecitabine in advanced breast cancer

Dr Peter Kaufman – Norris-Cotton Cancer Center, Lebanon, USA

Eribulin fails to demonstrate superiority over capecitabine in advanced breast cancer ( Dr Peter Kaufman – Norris-Cotton Cancer Center, Lebanon, USA )

Mammographic density and the risk and detection of breast cancer

Dr Norman Boyd – University of Toronto, Canada

Mammographic density and the risk and detection of breast cancer ( Dr Norman Boyd – University of Toronto, Canada )

Validation of genomic grade index histological grading in invasive breast cancer

Prof Christos Sotiriou – Jules Bordet Institute, Brussels, Belgium

Validation of genomic grade index histological grading in invasive breast cancer ( Prof Christos Sotiriou – Jules Bordet Institute, Brussels, Belgium )

Results of the TACT2 and BEATRICE breast cancer trials

Prof David Cameron – Edinburgh University, UK

Results of the TACT2 and BEATRICE breast cancer trials ( Prof David Cameron – Edinburgh University, UK )

Influence of low penetrant factors on overall cancer risk

Prof Douglas Easton – Cancer Research UK Genetic Epidemiology Unit, Cambridge University, UK

Influence of low penetrant factors on overall cancer risk ( Prof Douglas Easton – Cancer Research UK Genetic Epidemiology Unit, Cambridge University, UK )

Diverse genetic alterations found in triple-negative breast cancers after neoadjuvant chemo

Dr Justin Balko – Vanderbilt-Ingram Cancer Center, Nashville, USA

Diverse genetic alterations found in triple-negative breast cancers after neoadjuvant chemo ( Dr Justin Balko – Vanderbilt-Ingram Cancer Center, Nashville, USA )

A new oestrogen receptor protein target

Dr Jason Carroll – University of Cambridge, UK

A new oestrogen receptor protein target ( Dr Jason Carroll – University of Cambridge, UK )

Ethical issues associated with genomic sequencing

Dr James Evans – University of North Carolina, Chapel Hill, USA

Ethical issues associated with genomic sequencing ( Dr James Evans – University of North Carolina, Chapel Hill, USA )

Links between EGFR/HER1 signalling and trastuzumab efficacy

Dr David Rimm – Yale University, New Haven, USA

Links between EGFR/HER1 signalling and trastuzumab efficacy ( Dr David Rimm – Yale University, New Haven, USA )

Use of FDG PET imaging

Dr David Mankoff - University of Pennsylvania, Philadelphia

Use of FDG PET imaging ( Dr David Mankoff - University of Pennsylvania, Philadelphia )

Effects of obesity in breast cancer patients

Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA

Effects of obesity in breast cancer patients ( Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA )

The AZURE translational study

Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK

The AZURE translational study ( Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK )

Diagnosis of blood cancer after a breast cancer diagnosis

Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA

Diagnosis of blood cancer after a breast cancer diagnosis ( Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA )

HDAC inhibition sensitises triple-negative breast cancer cells to PARP inhibition

Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA

HDAC inhibition sensitises triple-negative breast cancer cells to PARP inhibition ( Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA )

A need for clarity in clinical trial end points

Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA

A need for clarity in clinical trial end points ( Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA )

Neratinib shows beneficial effects in the treatment of HER2 mutated breast cancer

Prof Ron Bose – Washington University School of Medicine, St. Louis, USA

Neratinib shows beneficial effects in the treatment of HER2 mutated breast cancer ( Prof Ron Bose – Washington University School of Medicine, St. Louis, USA )

Adjuvant chemotherapy for locally recurrent breast cancer

Dr Stefan Aebi – Luzerner Kantonsspital, Switzerland

Adjuvant chemotherapy for locally recurrent breast cancer ( Dr Stefan Aebi – Luzerner Kantonsspital, Switzerland )

Breast cancer hypo-fractionated radiotherapy offers long-term tumour control

Prof John Yarnold – Institute of Cancer Research and Royal Marsden Hospital, UK

$Breast cancer hypo-fractionated radiotherapy offers long-term tumour control ( Prof John Yarnold – Institute of Cancer Research and Royal Marsden Hospital, UK )$

Effectiveness of sentinel lymph node surgery after chemotherapy in node-positive breast cancer

Dr Judy Boughey – Mayo Clinic, Rochester USA

Effectiveness of sentinel lymph node surgery after chemotherapy in node-positive breast cancer ( Dr Judy Boughey – Mayo Clinic, Rochester USA )

Extending adjuvant trastuzumab treatment time provided no additional benefit

Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium

Extending adjuvant trastuzumab treatment time provided no additional benefit ( Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium )

Breast cancer genome sequencing identified HER2 mutations as targets for drug treatment

Prof Ron Bose - Washington University School of Medicine, St Louis, USA

Breast cancer genome sequencing identified HER2 mutations as targets for drug treatment ( Prof Ron Bose - Washington University School of Medicine, St Louis, USA )

Cognitive problems may be present before chemotherapy in women with breast cancer

Prof Bernadine Cimprich - University of Michigan School of Nursing, Ann Arbor, USA

Cognitive problems may be present before chemotherapy in women with breast cancer ( Prof Bernadine Cimprich - University of Michigan School of Nursing, Ann Arbor, USA )

BEATRICE study, adjuvant bevacizumab did not improve invasive disease-free survival in triple-negative breast cancer

Prof David Cameron - Edinburgh University, UK

BEATRICE study, adjuvant bevacizumab did not improve invasive disease-free survival in triple-negative breast cancer ( Prof David Cameron - Edinburgh University, UK )

Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer

Dr Peter Kaufman - Norris Cotton Cancer Center, New Hampshire, USA

Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer ( Dr Peter Kaufman - Norris Cotton Cancer Center, New Hampshire, USA )

HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment

Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA

HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment ( Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA )

Diverse genetic alterations in triple-negative breast cancers after neoadjuvant chemotherapy

Dr Justin Balko - Vanderbilt-Ingram Cancer Center, Nashville, USA

Diverse genetic alterations in triple-negative breast cancers after neoadjuvant chemotherapy ( Dr Justin Balko - Vanderbilt-Ingram Cancer Center, Nashville, USA )

Young women with breast cancer more likely to respond to neoadjuvant chemotherapy

Prof Sibylle Loibl - University of Frankfurt, Frankfurt, Germany

Young women with breast cancer more likely to respond to neoadjuvant chemotherapy ( Prof Sibylle Loibl - University of Frankfurt, Frankfurt, Germany )

Chemo after complete surgical removal of local or regional breast cancer recurrence increases survival rates

Dr Stefan Aebi - Luzerner Kantonsspital, Luzern, Switzerland

Chemo after complete surgical removal of local or regional breast cancer recurrence increases survival rates ( Dr Stefan Aebi - Luzerner Kantonsspital, Luzern, Switzerland )

Fewer, bigger doses of radiotherapy benefit cancer patients

Prof John Yarnold - Institute of Cancer Research and Royal Marsden Hospital, UK

Fewer, bigger doses of radiotherapy benefit cancer patients ( Prof John Yarnold - Institute of Cancer Research and Royal Marsden Hospital, UK )

More from ecancer